{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:43:20Z","timestamp":1761093800326,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.anai.2016.02.008","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T05:16:05Z","timestamp":1459746965000},"page":"274-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Direct comparison of efficacy of sublingual immunotherapy tablets for rhinoconjunctivitis"],"prefix":"10.1016","volume":"116","author":[{"given":"D\u00e9sir\u00e9e","family":"Larenas-Linnemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2016.02.008_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1398-9995.2011.02669.x","article-title":"European Academy of Allergy and Clinical Immunology task force report on \u2018dose-response relationship in allergen-specific immunotherapy\u2019","volume":"66","author":"Calderon","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.anai.2011.07.001","article-title":"Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units","volume":"107","author":"Larenas-Linnemann","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/all.12694","article-title":"Variation in allergen content in sublingual allergen immunotherapy (SLIT) with house dust mites (HDM)","volume":"70","author":"Moreno Benitez","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib4","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/j.1398-9995.2009.02040.x","article-title":"Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy","volume":"64","author":"Sander","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib5","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1398-9995.2006.01190.x","article-title":"Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children","volume":"61","author":"Valovirta","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2500\/aap.2008.29.3093","article-title":"Sublingual immunotherapy: dosing in relation to clinical and immunological efficacy","volume":"29","author":"Larenas-Linnemann","year":"2008","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2016.02.008_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1398-9995.2007.01365.x","article-title":"Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study","volume":"62","author":"Alvarez-Cuesta","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1398-9995.2010.02535.x","article-title":"Immunological mechanisms of sublingual allergen-specific immunotherapy","volume":"66","author":"Novak","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib9","first-page":"164","article-title":"Adjuvants and vector systems for the sublingual route","volume":"97","author":"Moingeon","year":"2013","journal-title":"Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess"},{"key":"10.1016\/j.anai.2016.02.008_bib10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/all.12383","article-title":"Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper","volume":"69","author":"Pfaar","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ACI.0000000000000062","article-title":"Patient-reported outcomes and quality-of-life questionnaires in the assessment of rhinoconjunctivitis in childhood","volume":"14","author":"Larenas-Linnemann","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.anai.2010.11.020","article-title":"European and Mexican vs US diagnostic extracts of Bermuda grass and cat in skin testing","volume":"106","author":"Larenas-Linnemann","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.aller.2009.11.005","article-title":"A\u00a0comparison of in\u00a0vitro potency between European and Mexican allergen extracts and US (CBER\/FDA) reference extracts","volume":"38","author":"Larenas-Linnemann","year":"2010","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.anai.2016.02.008_bib14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaci.2012.08.032","article-title":"Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE","volume":"130","author":"Cox","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaci.2005.12.1358","article-title":"Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis","volume":"117","author":"Durham","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2006.05.003","article-title":"Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis","volume":"118","author":"Dahl","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/cea.12324","article-title":"Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy","volume":"44","author":"Archila","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jaci.2011.06.022","article-title":"Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis","volume":"128","author":"Didier","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/all.12074","article-title":"Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects","volume":"68","author":"Nelson","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/all.12373","article-title":"Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure","volume":"69","author":"Durham","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaci.2014.09.049","article-title":"Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response","volume":"135","author":"Shamji","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1398-9995.2009.02232.x","article-title":"The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper","volume":"64","author":"Bousquet","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1517\/14740338.2015.1017468","article-title":"Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review","volume":"14","author":"Didier","year":"2015","journal-title":"Exp Opin Drug Saf"},{"key":"10.1016\/j.anai.2016.02.008_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-015-0057-8","article-title":"Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score","volume":"5","author":"Didier","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib26","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1398-9995.2007.01416.x","article-title":"Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy","volume":"62","author":"Calderon","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib27","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2012.08.012","article-title":"Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison","volume":"130","author":"Di Bona","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib28","unstructured":"GRADE Working Group. GRADE assign quality of evidence. http:\/\/homepage3.nifty.com\/aihara\/sakusaku\/GRADE-eng.html. Accessed September 25, 2015."},{"key":"10.1016\/j.anai.2016.02.008_bib29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaci.2007.10.039","article-title":"Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years","volume":"121","author":"Dahl","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","article-title":"SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial","volume":"129","author":"Durham","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1, pt 2","key":"10.1016\/j.anai.2016.02.008_bib31","first-page":"e174","article-title":"Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy","volume":"21","author":"Nieminen","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaci.2008.10.044","article-title":"Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy","volume":"123","author":"Bufe","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2010.11.034","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents","volume":"127","author":"Blaiss","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.anai.2013.11.018","article-title":"Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial","volume":"112","author":"Maloney","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib35","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jaci.2007.07.046","article-title":"Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis","volume":"120","author":"Didier","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cea.12100","article-title":"Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis","volume":"43","author":"Didier","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaci.2008.10.009","article-title":"Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis","volume":"123","author":"Wahn","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib38","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1399-3038.2010.01050.x","article-title":"Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents","volume":"21","author":"Halken","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaci.2009.06.006","article-title":"Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber","volume":"124","author":"Horak","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2500\/ajra.2014.28.4091","article-title":"Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis","volume":"28","author":"Bozek","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2012.04.021","article-title":"Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy","volume":"130","author":"Swamy","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib42","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jaci.2012.06.047","article-title":"High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study","volume":"130","author":"Wahn","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1398-9995.2011.02758.x","article-title":"Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children","volume":"67","author":"Stelmach","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2500\/aap.2011.32.3423","article-title":"Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy","volume":"32","author":"Panzner","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2016.02.008_bib45","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.rmed.2008.03.024","article-title":"Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually","volume":"102","author":"Panzner","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2016.02.008_bib46","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1398-9995.2009.02194.x","article-title":"Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study","volume":"64","author":"Ott","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib47","first-page":"177","article-title":"Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and\/or asthma due to grass pollen","volume":"41","author":"Agostinis","year":"2009","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib48","first-page":"175","article-title":"Efficacy of sublingual swallow immunotherapy in children with rye grass pollen allergic rhinitis: a double-blind placebo-controlled study","volume":"11","author":"Ahmadiafshar","year":"2012","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jaci.2005.11.014","article-title":"Efficacy and safety of specific\u00a0immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis","volume":"117","author":"Frew","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1067\/mai.2001.112027","article-title":"Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial","volume":"107","author":"Walker","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.02.008_bib51","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJM199908123410702","article-title":"Long-term clinical efficacy of grass-pollen immunotherapy","volume":"341","author":"Durham","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2016.02.008_bib52","first-page":"489","article-title":"A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy","volume":"51","author":"Dolz","year":"1996","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib53","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1046\/j.1365-2222.2001.01145.x","article-title":"Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study","volume":"31","author":"Leynadier","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.0954-7894.2002.01327.x","article-title":"Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial","volume":"32","author":"Lima","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13601-015-0061-z","article-title":"\u201cThe value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis\u201d","volume":"5","author":"Demoly","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.anai.2016.02.008_bib56","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/11634270-000000000-00000","article-title":"Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX(R)) in a real-life setting for three consecutive seasons: the GRAAL trial","volume":"32","author":"Wessel","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.anai.2016.02.008_bib57","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.clinthera.2011.06.006","volume":"33","author":"Reich","year":"2011","journal-title":"Clin Ther"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:14:25Z","timestamp":1761052465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120616000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1081120616000958"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2016.02.008","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct comparison of efficacy of sublingual immunotherapy tablets for rhinoconjunctivitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2016.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}